Colleen Kusy
Stock Analyst at Baird
(0.99)
# 3,745
Out of 4,941 analysts
48
Total ratings
29.27%
Success rate
-12.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $23.90 | +109.21% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $76.67 | +46.08% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $18.83 | +176.16% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.81 | +24.74% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $18.09 | +126.64% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $0.92 | +555.09% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.92 | +308.29% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $100 → $75 | $6.07 | +1,135.58% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $12.48 | +36.27% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $9.52 | +162.61% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.06 | +5,072.41% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.23 | +1,424.66% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.16 | +10,548.15% | 1 | Nov 2, 2021 |
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $23.90
Upside: +109.21%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $76.67
Upside: +46.08%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $18.83
Upside: +176.16%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.81
Upside: +24.74%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $18.09
Upside: +126.64%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.92
Upside: +555.09%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.92
Upside: +308.29%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $6.07
Upside: +1,135.58%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $12.48
Upside: +36.27%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.52
Upside: +162.61%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.06
Upside: +5,072.41%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.23
Upside: +1,424.66%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.16
Upside: +10,548.15%